Under pressure, Peter Hecht splits Ironwood into two biotechs, spinning out an R&D operation

Ironwood $IRWD is splitting up its business into two distinct halves, spinning out a pipeline of early- and mid-stage drugs into a separate, publicly traded biotech company while keeping its marketed products and related development projects in house at a scaled down, and more profitable, mother company.